Generic Price-Fixing: Sandoz Employee Notebook Provides Evidence For AGs' Third Suit

Complaint names 26 generic dermatologic drug manufacturers and 10 individual executives as defendants, alleging they engaged in a widespread conspiracy to artificially inflate and manipulate prices. State attorneys general say that structural and personnel changes at the companies fostered and facilitated collusion.

graphic in State AG complaint on generic price fixing
The state AGs' complaint includes a graphic showing the interlocking web of communications and relationships between executives at several of the corporate defendants and their key competitors. Each line in the graphic demonstrates that at least one phone call or text message was sent between those executives (identified by their initials) while they were competitors. For many of these executives, there were hundreds of calls and texts with competitors. • Source: State AGs' complaint

State attorneys general honed in on another segment of the generic drug industry, topical products, in their third suit alleging manufacturers and individual executives engaged in an overarching conspiracy to allocate markets and fix prices.

The allegations in the 593-page complaint, filed 10 June in the US District Court for the District of Connecticut,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Generics

Philippines Seeks Feedback On Plan To Recognize BE Studies Under ASEAN Deal

The Philippines medicines regulator explains how it intends to implement the ASEAN mutual recognition agreement under which member states have committed to accept bioequivalence study reports for generics issued by approved BE centers.

Finance Watch: Many Mega-Rounds, Some Smaller VC Deals, But Few In The Middle-Test-Sabbah

 
• By 

Private Company Edition: June’s eight $100m-plus venture capital rounds already outpace the seven each raised in March, April and May, including €255m ($274.2m) for ITM and $200m for Upstream, but while there were five $25m or less VC financings during the past week, mid-sized deals were lacking.

Novartis Takes Fight To The FDA After US Entresto Generic Approval

 
• By 

Novartis continues to fight tooth and nail to protect its $3bn Entresto brand in the US following the latest FDA approval of a generic version.

Covid

More from Biosimilars & Generics

Facility Deficiencies Drive Rising CRL Rates For CDER Biologics

 

A US FDA analysis found that facility inspection issues were the fastest growing factor in the recent rise of complete response letters for biologics licensing applications, in part reflecting the limitations of single-product inspections at contract facilities manufacturing multiple products.

Novartis Takes Fight To The FDA After US Entresto Generic Approval

 
• By 

Novartis continues to fight tooth and nail to protect its $3bn Entresto brand in the US following the latest FDA approval of a generic version.

EU Biosimilar Filings, Opinions And Approvals

 
• By 

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.